The PPGL market is evolving through advanced diagnostic techniques and novel treatment approaches. Leading companies including Progenics Pharmaceuticals, Lexicon Pharmaceuticals, and RayzeBio are developing innovative radioligand therapies and targeted agents that improve tumor management and patient outcomes. Enhanced genetic screening and personalized treatment protocols are refining clinical strategies for these rare endocrine tumors.
View Full Analysis: https://shorturl.at/UNpYz
Comment
Share
